IL204958A0 - Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs) - Google Patents

Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs)

Info

Publication number
IL204958A0
IL204958A0 IL204958A IL20495810A IL204958A0 IL 204958 A0 IL204958 A0 IL 204958A0 IL 204958 A IL204958 A IL 204958A IL 20495810 A IL20495810 A IL 20495810A IL 204958 A0 IL204958 A0 IL 204958A0
Authority
IL
Israel
Prior art keywords
mglurs
modulators
metabotropic glutamate
glutamate receptors
tetrazole derivatives
Prior art date
Application number
IL204958A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Erwan Arzel
Louise Edwards
Methvin Isaac
Donald A Mcleod
Abdelmalik Slassi
Tao Xin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL204958(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Erwan Arzel, Louise Edwards, Methvin Isaac, Donald A Mcleod, Abdelmalik Slassi, Tao Xin filed Critical Astrazeneca Ab
Publication of IL204958A0 publication Critical patent/IL204958A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL204958A 2007-10-19 2010-04-08 Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs) IL204958A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98129407P 2007-10-19 2007-10-19
PCT/SE2008/051170 WO2009051556A1 (en) 2007-10-19 2008-10-17 Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs)

Publications (1)

Publication Number Publication Date
IL204958A0 true IL204958A0 (en) 2010-11-30

Family

ID=40567640

Family Applications (1)

Application Number Title Priority Date Filing Date
IL204958A IL204958A0 (en) 2007-10-19 2010-04-08 Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs)

Country Status (21)

Country Link
US (1) US7960422B2 (enExample)
EP (1) EP2231647A4 (enExample)
JP (1) JP2011500673A (enExample)
KR (1) KR20100090777A (enExample)
CN (1) CN101896480A (enExample)
AR (1) AR068921A1 (enExample)
AU (1) AU2008312055A1 (enExample)
BR (1) BRPI0818448A2 (enExample)
CA (1) CA2703425A1 (enExample)
CL (1) CL2008003085A1 (enExample)
CO (1) CO6321281A2 (enExample)
CR (1) CR11376A (enExample)
DO (1) DOP2010000119A (enExample)
EA (1) EA201000654A1 (enExample)
IL (1) IL204958A0 (enExample)
MX (1) MX2010004272A (enExample)
PE (1) PE20090875A1 (enExample)
TW (1) TW200934771A (enExample)
UY (1) UY31403A1 (enExample)
WO (1) WO2009051556A1 (enExample)
ZA (1) ZA201002694B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
RU2500681C2 (ru) 2007-10-19 2013-12-10 Берингер Ингельхайм Интернациональ Гмбх Замещенные гетероциклом пиперазинодигидротиенопиримидины
SI2610258T1 (sl) 2007-10-19 2014-12-31 Boehringer Ingelheim International Gmbh Substituirani piperidino-dihidrotienopirimidini
EP2215093B1 (de) 2007-10-19 2011-12-14 Boehringer Ingelheim International GmbH Neue piperazino-dihydrothienopyrimidin-derivate
MY154000A (en) 2008-09-22 2015-04-30 Cayman Chem Co Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
EP2379531A1 (en) * 2008-12-18 2011-10-26 AstraZeneca AB Processes for the manufacture of 3-{4-methyl-5- [ (ir) -1- (2- (3-methylphenyl) -2h-tetrazol-5-yl) -ethoxy]-4h- [1,2, 4]triazol-3-yl} -pyridine, 4-methyl-3-methylthio-5- (3- pyridyl)-l,2,4-triazole, and (ir) -1- [2- (3-methylphenyl) -2h- tetrazol-5-yl]ethanol
EP2438052A1 (en) * 2009-06-05 2012-04-11 Oslo University Hospital HF Azole derivatives as wtn pathway inhibitors
CN103429583A (zh) 2010-12-08 2013-12-04 奥斯陆大学医院公司 作为wnt信号通路抑制剂的三唑衍生物
EA201391348A8 (ru) 2011-03-18 2014-11-28 Новартис Аг КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
CN106032377A (zh) * 2015-03-12 2016-10-19 天津药物研究院有限公司 四氮唑类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663332A (en) * 1985-10-10 1987-05-05 Hoffman-La Roche Inc. 5-substituted N-alkylated tetrazoles
US5492919A (en) 1991-08-03 1996-02-20 Smithkline Beecham P.L.C. 5-HT4 receptor antagonists
DE10023430A1 (de) 2000-05-12 2001-11-15 Bayer Ag Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
CA2462289C (en) 2001-10-04 2010-02-23 Nicholas D. Cosford Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
EP1485093B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
WO2004014881A2 (en) * 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005080356A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
SG149900A1 (en) 2004-02-18 2009-02-27 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AU2005214375A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200811157A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
TW200811156A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators IV

Also Published As

Publication number Publication date
UY31403A1 (es) 2009-05-29
EP2231647A4 (en) 2011-08-31
AR068921A1 (es) 2009-12-16
PE20090875A1 (es) 2009-08-08
TW200934771A (en) 2009-08-16
DOP2010000119A (es) 2010-05-31
BRPI0818448A2 (pt) 2015-05-12
AU2008312055A1 (en) 2009-04-23
CR11376A (es) 2010-07-19
EA201000654A1 (ru) 2010-12-30
US20090131454A1 (en) 2009-05-21
ZA201002694B (en) 2011-03-30
EP2231647A1 (en) 2010-09-29
CN101896480A (zh) 2010-11-24
MX2010004272A (es) 2010-04-30
CO6321281A2 (es) 2011-09-20
KR20100090777A (ko) 2010-08-17
US7960422B2 (en) 2011-06-14
WO2009051556A1 (en) 2009-04-23
CL2008003085A1 (es) 2009-10-09
JP2011500673A (ja) 2011-01-06
CA2703425A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
ZA201002694B (en) Tetrazole derivetives as modulators of metabotropic glutamate receptors(mglurs)
IL201995A0 (en) Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
IL187189A0 (en) Novel heterocyclic compounds as positive allosteric modulators of metabotropic glutamate receptors
IL179692A0 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
IL187186A0 (en) Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
IL200851A0 (en) Novel tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors
IL200922A0 (en) 8-oxy-quinoline derivatives as bradykinin b2 receptor modulators
PL2134685T3 (pl) Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1
IL201569A0 (en) 2-pyridine carboxamide derivatives as sodium channel modulators
ATE502938T1 (de) Pyridinderivate als s1p1/edg1-rezeptormodulatoren
IL189617A0 (en) Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
IL219149A0 (en) Novel oxime derivatives and thier use as allosteric modulators of metabotropic glutamate receptors
EP2097384A4 (en) INDOZALYL SULFOMNAMIDE DERIVATIVES USEFUL AS MODULATORS OF GLUCOCORTICOIDS
IL210067A0 (en) Pyridinylpiperazin derivatives useful as modulators of dopamine d3 receptors
ZA200801641B (en) Chromenones and their use as modulators of metabotropic glutamate receptors
IL198648A0 (en) Novel triazinedione derivatives as gaba-b receptor modulators
IL204888A0 (en) Thiophene - 2 - carboxamide derivatives as modulators of ccr9 receptor
HK1148282A (en) Tetrazole derivates as modulators of metabotropic glutamate receptors (mglurs)
ZA200710278B (en) Substituted Oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
EP2459190A4 (en) HEXAHYDROCYCLOPENTYL - [?] INDAZOLE-5-HYDROXYMETHYL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
HK1142061A (en) Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
GB0507793D0 (en) Allosteric modulators of glutamate receptors
AU2007907046A0 (en) Modulation of GABAbeta receptors